{
  "id": 20311193,
  "title": "Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study",
  "url": "https://urgent.news/2026/11/16/lexeo-therapeutics-cuts-arrhythmia-burden-by-80-in-genetic-heart",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-16T18:31:43.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/trading-ideas/movers/26/11/63311182/lexeo-therapeutics-cuts-arrhythmia-burden-by-80-in-genetic-heart-disease-study"
  },
  "original_language": "en",
  "account": null,
  "summary": "Lexeo Therapeutics Inc. (NASDAQ:LXEO) has announced positive interim results from its HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The high-dose cohort of the study showed an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) from baseline, with six of seven patients experiencing improvement. Cardiac MRIs also revealed stabilized or improved right ventricular function in most high-dose patients. The safety profile of LX2020 was generally favorable, with no discontinuations or clinically significant complement activation reported. Lexeo expects to finalize its pivotal study design and start the trial in late 2027, with its cash runway extending into 2028.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}